(Q39396683)

11 September 2017

title

Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma (English)

1 reference

11 September 2017

R Fonseca

4

0 references

author name string

G Cesarman-Maus

series ordinal

1

1 reference

11 September 2017

E Braggio

series ordinal

2

1 reference

11 September 2017

H Maldonado

series ordinal

3

1 reference

11 September 2017

publication date

15 February 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

26

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

1671-1674

1 reference

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Genetic link between cancer and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Tissue factor-bearing microparticles and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Microparticle-associated tissue factor activity: a link between cancer and thrombosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Thrombin signalling and protease-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Emerging insights in tissue factor-dependent signaling events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Role of tissue factor in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Venous thromboembolism in the hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

A possible link between Trousseau's syndrome and tissue factor producing plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

7 January 2021

inferred from DOI database lookup

A subpopulation of human B lymphocytes can express a functional Tissue Factor in response to phorbol myristate acetate.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

7 January 2021

inferred from DOI database lookup

Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.43

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/LEU.2012.43

1 reference

Dimensions Publication ID

11 September 2017

1023707502

0 references

Fatcat ID

release_adt3mpnz5fb55pj72dpihorrle

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/adt3mpnz5fb55pj72dpihorrle

24 November 2022

mapped directly with Wikidata item

1 reference